Pds biotechnology announces oncology research and development day

Florham park, n.j., june 14, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the company's proprietary versamune® t-cell activating technology, today announced it will host an oncology r&d day for analysts, investors, and the scientific community on wednesday, june 16th.
PDSB Ratings Summary
PDSB Quant Ranking